What the Evidence Really Says About Cannabis, Depression and Mental Health

Medical cannabis is often discussed as a possible treatment for depression, anxiety, post-traumatic stress disorder (PTSD), bipolar disorder and ADHD. But the strongest available evidence does not support the broad claim that cannabis is an established treatment for these conditions.

The distinction matters. Some people report feeling less anxious or depressed shortly after using cannabis, but short-term symptom relief is not the same as treating an underlying disorder. Cannabis products also vary widely in their THC and CBD content, and the effects can differ according to dose, frequency of use, diagnosis and individual vulnerability.

Depression: reports of relief, but no proven treatment benefit

A 2024 systematic review of 78 studies found that cannabis use was associated with more depressive and manic symptoms in the general population, as well as a greater likelihood of major depressive disorder and bipolar disorder. The authors also reported links between cannabis use and poorer outcomes among people who already had a mood disorder. Because much of this evidence was observational, it cannot by itself prove that cannabis causes depression; people may use cannabis in response to existing symptoms, and other factors may influence both cannabis use and mental health.

More controlled evidence is less encouraging. A 2026 systematic review and meta-analysis of randomized trials found a trivial-to-no effect of cannabinoids on depression symptoms. The authors concluded that the evidence was too uncertain to support cannabinoids as a first-line treatment and found no clear benefit for depression.

This does not mean that every person experiences cannabis in the same way. It does mean that cannabis should not be presented as a clinically validated substitute for established depression treatments, such as psychotherapy, antidepressant medication when appropriate, or other treatments recommended by a qualified clinician.

What the Washington State study actually found

Consider a 2018 Washington State University study, “A naturalistic examination of the perceived effects of cannabis on negative affect”. Participants used cannabis in their everyday environments and reported their symptoms before and after use.

The study found that participants perceived short-term reductions in depression, anxiety and stress. Products higher in CBD and lower in THC were associated with some of the reported changes, although the pattern varied by symptom and dose.

Those findings are useful for generating research questions, but they do not establish that cannabis treats depression. The study was naturalistic rather than a randomized, placebo-controlled clinical trial. Participants chose what to use, knew they were using cannabis and reported their own symptoms. Expectation effects, differences among users and the temporary effects of intoxication could therefore influence the results. The study also raised a longer-term concern: repeated use may worsen baseline depressive symptoms for some people.

Anxiety and PTSD

Some controlled studies suggest that particular cannabinoid preparations may reduce anxiety in limited circumstances. However, the evidence is inconsistent, and the 2026 meta-analysis noted that much of the anxiety research measured anxiety as a secondary outcome in studies focused on other medical conditions. THC can also trigger anxiety, paranoia or disorientation, particularly at higher doses or in people who are vulnerable to these effects.

PTSD has received considerable attention because some patients use cannabis to manage nightmares, insomnia and intrusive memories. Yet the evidence remains limited. The U.S. Department of Veterans Affairs’ clinical guidance for PTSD recommends against cannabis and cannabis derivatives because well-designed evidence of benefit is lacking and potential harms remain a concern. Trauma-focused psychotherapies remain the better-supported treatments.

Bipolar disorder and ADHD require particular caution

For bipolar disorder, cannabis is not a neutral option. The National Academies’ review of cannabis research found moderate evidence linking regular cannabis use with increased symptoms of mania and hypomania among people with bipolar disorder. A 2024 review likewise linked cannabis use with an unfavorable course for both major depression and bipolar disorder.

Claims about cannabis improving ADHD are also ahead of the evidence. Research has not established a reliable benefit, a standard dose or a safe treatment protocol, particularly for children and adolescents. Cannabis can impair attention, memory, learning and reaction time—functions that are already central to ADHD symptoms.

Risks and practical considerations

Cannabis use has been associated with psychosis, depression, social anxiety and suicidal thoughts or behavior, although the exact causal relationships are complex. The risk of psychosis is especially concerning for people with a personal or family history of psychotic disorders. Frequent use can also lead to cannabis use disorder, in which a person has difficulty reducing or stopping despite negative consequences.

The National Academies’ evidence review found substantial evidence of an association between cannabis use and schizophrenia or other psychoses, with the highest risk among the most frequent users. The Centers for Disease Control and Prevention likewise cautions that cannabis can cause anxiety and paranoia and has been linked with depression, suicidality and psychosis.

Anyone considering cannabis for a mental health condition should discuss it with a licensed health professional, especially if they take psychiatric medication, have bipolar disorder, have experienced psychosis or are pregnant. Cannabis should not replace proven treatment without medical supervision. A clinician can also help distinguish a temporary change in symptoms from a meaningful improvement in the condition itself.

The bottom line

Medical cannabis remains an active area of research, but the evidence does not justify describing it as a proven treatment for depression or most other psychiatric disorders. Some people report short-term relief, and specific cannabinoid medicines may eventually prove useful for particular symptoms or patients. For now, however, the research is limited, products are inconsistent, and potential harms—including worsening mood, mania, psychosis and cannabis use disorder—must be taken seriously.